Poster Number
35
Poster Title
TRECA: A Secure, Scalable Platform for National-Scale Genomic Medicine and Clinical Decision Support
Authors
Yatish Jain, Anuradha Wickramarachchi, Adrien Oliva, Natalie A Twine, Brendan Hosking, Mark Burgess, Christina Xu, Nick Edwards, Denis C. Bauer (CSIRO)
Abstract
The CSIRO Transformational Bioinformatics Group has developed TRECA (Trusted Research Environment and Clinical Applications)—a world-first, cloud-native platform supporting secure data sharing, high-throughput analysis, interoperability, and personalised clinical decision-making using genomic information.
Co-designed with the Indonesian Ministry of Health and funded through a competitive international United Nations Development Program tender, TRECA is already delivering significant clinical and economic impact. It supports pharmacogenomics (PGx) and rare disease diagnostics, enabling clinicians to optimise treatment, such as adjusting Clopidogrel therapy for atherosclerotic cardiovascular disease, where up to 33% of Indonesians are non-responders. It also enables early diagnosis of familial hypercholesterolemia (FH), affecting over 520,000 individuals, reducing risk of premature cardiovascular death.
The platform enables both clinical services and research by combining secure data governance with scalable compute. Built entirely in the cloud, TRECA provides a digital "vault" for sensitive patient data, compliant with Indonesian and Australian privacy laws. It includes a genomics data portal, distributed analytics environment, and containerised workflows that can be deployed across national biobanks and hospitals.
The platform implements and extends GA4GH Beacon through CSIRO’s population scalable cloud-based sBeacon platform (Nature Biotechnology, 2023) and integrates a cloud-native deployment of Ensembl’s Variant Effect Predictor (sVEP) for high-throughput variant interpretation. TRECA’s innovation lies in combining these within a secure, real-time clinical decision-support system. The platform’s architecture builds on lessons from the UK Biobank Research Analysis Platform and incorporates key enhancements as published in RAPpoet (Scientific Reports, 2025).
Plans are also underway to extend TRECA into infectious disease genomics and pandemic surveillance. Supporting over 1 million patients and projecting AUD 5.5M in annual healthcare savings, TRECA demonstrates how secure, interoperable, and standards-aware platforms can translate genomic science into clinical and public health benefit, bridging the gap between discovery and delivery.
Co-designed with the Indonesian Ministry of Health and funded through a competitive international United Nations Development Program tender, TRECA is already delivering significant clinical and economic impact. It supports pharmacogenomics (PGx) and rare disease diagnostics, enabling clinicians to optimise treatment, such as adjusting Clopidogrel therapy for atherosclerotic cardiovascular disease, where up to 33% of Indonesians are non-responders. It also enables early diagnosis of familial hypercholesterolemia (FH), affecting over 520,000 individuals, reducing risk of premature cardiovascular death.
The platform enables both clinical services and research by combining secure data governance with scalable compute. Built entirely in the cloud, TRECA provides a digital "vault" for sensitive patient data, compliant with Indonesian and Australian privacy laws. It includes a genomics data portal, distributed analytics environment, and containerised workflows that can be deployed across national biobanks and hospitals.
The platform implements and extends GA4GH Beacon through CSIRO’s population scalable cloud-based sBeacon platform (Nature Biotechnology, 2023) and integrates a cloud-native deployment of Ensembl’s Variant Effect Predictor (sVEP) for high-throughput variant interpretation. TRECA’s innovation lies in combining these within a secure, real-time clinical decision-support system. The platform’s architecture builds on lessons from the UK Biobank Research Analysis Platform and incorporates key enhancements as published in RAPpoet (Scientific Reports, 2025).
Plans are also underway to extend TRECA into infectious disease genomics and pandemic surveillance. Supporting over 1 million patients and projecting AUD 5.5M in annual healthcare savings, TRECA demonstrates how secure, interoperable, and standards-aware platforms can translate genomic science into clinical and public health benefit, bridging the gap between discovery and delivery.
Digital Poster